October 14, 2021 01:40 PM Eastern Daylight Time

PHILADELPHIA--( BUSINESS WIRE )-- PCI Pharma Services , the world's leading provider of integrated pharmaceutical and biopharmaceutical solutions, announced that the company has signed a definitive agreement to acquire Permira, a global private equity firm Lyophilization Services of New England, Inc. (LSNE). Founded in 1997, LSNE is an important commissioned development and production organization (CDMO) headquartered in Bedford, New Hampshire. It has an excellent history of providing services to global pharmaceutical, biotechnology and medical device companies. The advantage lies in the high-quality cGMP aseptic filling ability, as well as the expertise and ability in large-scale freeze-drying production. Freeze drying is an important process commonly used in injections and biological therapies. After the acquisition of LSNE, PCI will transform into a global CDMO based on the consolidation of the original biologics packaging and professional production expertise, and expand the company's service range. This acquisition brings to PCI five facilities in the United States (New Hampshire, Wisconsin) and Europe (Spain) that have been approved by the U.S. Food and Drug Administration (FDA). The sixth facility is expected to be in the future. Approved within a few months, and three other facilities are under development. The new facility will expand PCI's global network to 30.

Salim Haffar, CEO of PCI Pharma Services, said: "We warmly welcome LSNE to join the PCI family. PCI is committed to bringing life-changing therapies to patients around the world, and LSNE has a passion for patients, a talented team, a sound regulatory compliance culture, Operational excellence and innovative methods to meet customer challenges are highly compatible with our global strategy. What makes us particularly excited is that this acquisition will expand our global manufacturing capabilities and make us a single source for customer drug development and packaging needs , Reduce the complexity of the supply chain, and speed up the launch of products to meet the urgent needs of the market."

With the addition of LSNE, PCI will be able to provide comprehensive macromolecular and small molecule solutions for its clinical and commercial customers. With the improvement of global production capacity, PCI can provide a wide range of complex formulation injections, high-performance injections, and freeze-dried injections obtained through this acquisition, including nanoparticles, mRNA, mAB, proteins, oligonucleotides and others Biological preparations, packaging forms include vials, bottles, pre-filled syringes and auto-injectors.

Matt Halvorsen, Founder and CEO of LSNE, said: "We are very happy to join the PCI team and look forward to enabling our employees and customers to smoothly integrate into the new environment. Both companies place great emphasis on innovation, quality, excellent customer service and company employees. Working hand in hand with a global industry leader like PCI is a big step forward for LSNE. This successful merger transaction will benefit both customers, employees, and patients that they serve together."

The acquisition of LSNE is PCI's fourth acquisition in the past three years, which also demonstrates that PCI is committed to strengthening the company's global professional manufacturing capabilities while consolidating its existing clinical and commercial packaging expertise. PCI Chairman Matt Jennings added: "We are pleased to support this strategic transformational investment on behalf of our investors to build a world-class integrated CDMO that will benefit patients, customers, employees, and shareholders. This milestone This type of transaction demonstrates PCI’s global strategy and commitment to become the partner of choice to meet the professional needs of customers.”

Jefferies LLC acted as exclusive financial advisor to PCI Pharma Services; Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to PCI Pharma Services.

PCI is headquartered in Philadelphia, Pennsylvania.

About PCI Pharma Services

The global healthcare industry trusts PCI's drug development solutions, which accelerate their time to market and increase their chances of commercial success. Only PCI provides proven experience, successfully launches more than 50 products every year, and operates the healthcare service business for more than 50 years. Leading technology and continuous investment enable us to meet the needs of global development throughout the product life cycle-from phase I clinical trials to commercialization and continuous supply. Our customers see us as an extension and partner of their business, working together to improve the lives of patients. For more information, please visit www.pciservices.com .

Disclaimer: The original version of this announcement is the officially authorized version. The translation is only for the convenience of understanding, please refer to the original text. The original text is the only legally valid version.

Contacts

Contact:
Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877